Zoledronic acid prevents decreases in bone mineral density in patients with prostate cancer undergoing combined androgen blockade

Zoledronic acid prevents decreases in bone mineral density in patients with prostate cancer undergoing combined androgen blockade

SpringerPlus, October 2014

25332886

Satoshi Nishizawa, Takeshi Inagaki, Akinori Iba, Kazuro Kikkawa, Yoshiki Kodama, Nagahide Matsumura, Yasuo Kohjimoto, Isao Hara

The aim of this study was to evaluate the effect of zoledronic acid (ZA) on bone mineral density (BMD) in patients with prostate cancer receiving combined androgen blockade (CAB) as a first-line androgen deprivation therapy. Patients receiving CAB for prostate cancer without bone metastasis were candidates for this study. Forty-two patients were randomly assigned to receive either ZA or no treatment. BMD were measured at baseline and at 12 months. Bone-turnover markers, including cross-linked N-telopeptide of type I collagen (NTX), C-telopeptide of type I collagen (ICTP), and bone-specific alkaline phosphatase (BAP), were assessed during study periods. Patients on ZA maintained BMD after a year of treatment. Change in T-score from baseline differed significantly between the two groups (P=0.009). An inverse correlation was demonstrated between baseline and change in T-score in the ZA group. While ZA prevented an increase in ICTP and BAP, the increase in NTX was suppressed only in patients with low baseline T-score. ZA prevented a decrease in BMD in patients undergoing CAB, especially those with lower baseline BMD.